These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 10754723)
21. On the accountability problem of the pharmaceutical industry. Roberts CD Pharmazie; 1973 Jan; 28(1):49-51. PubMed ID: 4714241 [No Abstract] [Full Text] [Related]
22. The role of the pharmaceutical industry in drug development and approval. Beleau MH Vet Hum Toxicol; 1998; 40 Suppl 2():17-9. PubMed ID: 9823577 [No Abstract] [Full Text] [Related]
23. Process analytical technologies in the pharmaceutical industry: the FDA's PAT initiative. Hinz DC Anal Bioanal Chem; 2006 Mar; 384(5):1036-42. PubMed ID: 16079977 [No Abstract] [Full Text] [Related]
25. Carleton's corner. Should the United States pharmacopeia define manufacturing process limits? Korczynski MS J Parenter Sci Technol; 1991; 45(2):76. PubMed ID: 2051259 [No Abstract] [Full Text] [Related]
26. Clinical investigators and the pharmaceutical industry. Bellin E N Engl J Med; 2000 Aug; 343(7):511. PubMed ID: 10950676 [No Abstract] [Full Text] [Related]
27. No time for doomsday. Stetler CJ Hosp Formul; 1975 May; 10(5):220-1, 225-6. PubMed ID: 10237838 [No Abstract] [Full Text] [Related]
28. PDA comments to USP on elastomeric closures for injection (381). Parenteral Drug Association. PDA J Pharm Sci Technol; 1997; 51(5):213-8. PubMed ID: 9357308 [No Abstract] [Full Text] [Related]
29. The path to good aseptic guidance. Johnson R; Miner D PDA J Pharm Sci Technol; 2004; 58(2):59-61. PubMed ID: 15113071 [No Abstract] [Full Text] [Related]
31. Evaluation of blend uniformity and content uniformity based on 2003 stratified sampling guidance and 1999 blend uniformity analysis guidance: product A. Howard-Sparks M; Gawlikowski A; PDA J Pharm Sci Technol; 2004; 58(4):222-30. PubMed ID: 15368992 [TBL] [Abstract][Full Text] [Related]
32. E2C(R2) Periodic Benefit-Risk Evaluation Report and E2C(R2) Periodic Benefit-Risk Evaluation Report--Questions and Answers; International Council for Harmonisation; Guidances for Industry; Availability. Notice. Food and Drug Administration, HHS Fed Regist; 2016 Jul; 81(138):46938-40. PubMed ID: 27459749 [TBL] [Abstract][Full Text] [Related]
33. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321 [TBL] [Abstract][Full Text] [Related]
34. Relationship of USP-NF to NDA and ANDA "Standards". Belson JJ Am J Hosp Pharm; 1982 May; 39(5):869-70. PubMed ID: 7081269 [No Abstract] [Full Text] [Related]
35. Strengthening drug manufacturing practices. Hecht A FDA Consum; 1976; 10(6):12-4. PubMed ID: 829227 [No Abstract] [Full Text] [Related]
37. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation? Orlando VI Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734 [No Abstract] [Full Text] [Related]
38. Toward more effective drug regulation. Schmidt AM FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532 [No Abstract] [Full Text] [Related]
39. Marketing off-label uses to physicians: FDA's draft (mis)guidance. Gass A; Wilson J Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084 [No Abstract] [Full Text] [Related]
40. Proposed US Food and Drug Administration guidance for industry on distributing medical publications about the risks of prescription drugs and biological products: a misguided approach. Wolfe SM JAMA Intern Med; 2014 Oct; 174(10):1543-4. PubMed ID: 25127222 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]